Friday, January 19, 2018 -- A combination of three therapies was found to provide the greatest benefit to patients with metastatic breast cancer classified as HER2- and hormone receptor-positive, who aren't candidates for chemotherapy, according to a Northwestern Medicine clinical trial.
Wednesday, January 17, 2018 -- An upcoming Phase 1b/2 trial will evaluate Syndax Pharmaceuticals‘ investigational therapy entinostat in combination with Genentech‘s Tecentriq (atezolizumab) in women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have received one previous line of therapy. The trial is part of a new clinical collaboration between the two companies. […] The post Syndax, Genentech to Test Combo Therapy for HR-positive, HER2-negative Metastatic Breast Cancer appeared first on Breast Cancer News.
Friday, January 19, 2018 -- Based on results from the phase III OlympiAD trial, the PARP inhibitor olaparib (Lynparza) has been approved by the FDA for the treatment of patients with germline BRCA-positive, metastatic breast cancer.
Thursday, January 18, 2018 -- An international team of researchers led from Karolinska Institutet and Science for Life Laboratory in Sweden have found a new way of halting the growth of breast cancer cells.
Friday, January 19, 2018 -- According to a recent Journal of the American College of Radiology, the ACR recommends women at an average risk for breast cancer should begin annual mammograms at age 40. High-risk women should start mammograms even earlier.
Wednesday, January 17, 2018 -- Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
Sunday, January 21, 2018 -- According to long-term follow-up results from the National Surgical Adjuvant Breast and Bowel Project B-31 trial published in the Journal of Clinical Oncology, trastuzumab (Herceptin) did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
Tuesday, January 16, 2018 -- Purpose: Therapeutic strategies against hormonal receptor–positive (HR+)/HER2+ breast cancers with poor response to trastuzumab need to be optimized. Experimental Design: Two HR+/HER2+ patient-derived xenograft (PDX) models named as COH-SC1 and COH-SC31 were established to explore targeted therapies for HER2+ breast cancers. RNA sequencing and RPPA (reverse phase protein array) analyses were conducted to decipher molecular features of the two PDXs and define the therapeutic strategy of interest, validated by in vivo drug efficacy examination and in vitro cell proliferation analysis. Results: Estrogen acted as a growth driver of trastuzumab-resistant COH-SC31 tumors but an accelerator in the trastuzumab-sensitive COH-SC1 model. In vivo trastuzumab efficacy examination further confirmed the consistent responses between PDXs and the corresponding tumors. Integrative omics analysis revealed
Tuesday, January 16, 2018 -- by Mohamed Khalis, Barbara Charbotel, Véronique Chajès, Sabina Rinaldi, Aurélie Moskal, Carine Biessy, Laure Dossus, Inge Huybrechts, Emmanuel Fort, Nawfel Mellas, Samira Elfakir, Hafida Charaka, Chakib Nejjari, Isabelle Romieu, Karima El Rhazi Background Breast cancer is the most common cancer in women worldwide. In the Moroccan context, the role of well-known reproductive factors in breast cancer remains poorly documented. The aim of this study was to explore the relationship between menstrual and reproductive factors and breast cancer risk in Moroccan women in the Fez region. Methods A case–control study was conducted at the Hassan II University Hospital of Fez between January 2014 and April 2015. A total of 237 cases of breast cancer and 237 age-matched controls were included.
Friday, January 19, 2018 -- Oncotype DX less cost-effective in real-world practice than under ideal conditions
Tuesday, January 16, 2018 -- The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.